Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LGVN Longeveron Inc

Market Closed 06-05 16:00:00 EDT

0.7300

-0.0700

-8.75%

盘后0.7300

+0.00000.00%

19:22 EDT

High0.8000	Low0.7200	Vol306.37K
Open0.8000	D1 Closing0.8000	Amplitude10.00%
Mkt Cap23.07M	Tradable Cap19.90M	Total Shares31.60M
T/O230.11K	T/O Rate1.12%	Tradable Shares27.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":0.73,"timestamp":1780689600000,"preClose":0.8,"halted":0,"volume":306373,"hourTrading":{"tag":"盘后","latestPrice":0.73,"preClose":0.73,"latestTime":"19:22 EDT","volume":453,"amount":336.2393,"timestamp":1780701751350,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.08750000000000008,"floatShares":27255300,"shares":31597952,"eps":-1.119466,"marketStatus":"Market Closed","change":-0.07,"latestTime":"06-05 16:00:00 EDT","open":0.8,"high":0.8,"low":0.72,"amount":230108.85587660002,"amplitude":0.1,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.119466,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":7,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":0.8,"preHourTrading":{"tag":"盘前","latestPrice":0.7874,"preClose":0.8,"latestTime":"09:15 EDT","volume":1378,"amount":1089.0367072,"timestamp":1780665342963,"change":-0.0126,"changeRate":-0.01575,"amplitude":0.01575},"postHourTrading":{"tag":"盘后","latestPrice":0.73,"preClose":0.73,"latestTime":"19:22 EDT","volume":453,"amount":336.2393,"timestamp":1780701751350,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.2927970836685951},"requestUrl":"/m/hq/s/LGVN/tweets","defaultTab":"tweets","newsList":[{"id":"2641412832","title":"Longeveron Announces CFO Transition to Internal Successor","url":"https://stock-news.laohu8.com/highlight/detail?id=2641412832","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641412832?lang=en_us&edition=fundamental","pubTime":"2026-06-06 05:19","pubTimestamp":1780694382,"startTime":"0","endTime":"0","summary":"Longeveron ( ($LGVN) ) has shared an announcement. On June 1, 2026, Longeveron Inc. announced that Chief Financial Officer Lisa Locklear will step ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeveron-announces-cfo-transition-to-internal-successor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeveron-announces-cfo-transition-to-internal-successor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641140304","title":"BRIEF-Longeveron -   On June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641140304","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641140304?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:35","pubTimestamp":1780691728,"startTime":"0","endTime":"0","summary":"BRIEF-Longeveron -   On June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026 - SEC FilingJune 5  - Longeveron Inc LGVN.O:LONGEVERON -   ON JUNE 1, LISA LOCKLEAR TO STEP DOWN AS CFO EFFECTIVE JULY 10, 2026 - SEC FILINGLONGEVERON - ANTICIPATES MARIE WASHBURN TO BE ELEVATED TO CFO PENDING FINAL CONTRACT - SEC FILINGSource text: [ID:n0001213900-26-065788]Further company coverage: LGVN.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D05C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641147045","title":"Longeveron -   on June 1, Lisa Locklear to Step Down as CFO Effective July 10, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641147045","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641147045?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:24","pubTimestamp":1780691047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D05C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641046147","title":"Longeveron - Anticipates Marie Washburn to Be Elevated to CFO Pending Final Contract - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641046147","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641046147?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:24","pubTimestamp":1780691047,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D05C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640892168","title":"Longeveron to present at BIO International Convention 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640892168","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640892168?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:15","pubTimestamp":1780578920,"startTime":"0","endTime":"0","summary":"Longeveron will attend the BIO International Convention on June 22-25, 2026 in San Diego.A corporate presentation is scheduled for June 24, 2026 at 2:15 p.m. PT.Management plans partnering meetings tied to laromestrocel programs in HLHS, Alzheimer’s disease, pediatric dilated cardiomyopathy, aging-related frailty.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL5Kyvvl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","LU2210149790.SGD","BK4139","SG9999014021.USD","LU0314104364.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4112","SG9999014005.SGD","IE00B3QW5Z07.USD","LGVN","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878512","title":"Longeveron shifts to capital-light model, targets licensing partners for laromestrocel","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878512","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878512?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:06","pubTimestamp":1779307612,"startTime":"0","endTime":"0","summary":"Longeveron shifted to a more capital-efficient plan centered on licensing partnerships for its stem cell therapy laromestrocel, aiming to rely on partners’ commercial scale and funding to advance development.Strategy prioritizes the Phase 2b ELPIS II readout in hypoplastic left heart syndrome, with top-line 12-month data expected in August 2026, to support FDA discussions on a potential path to a biologics license application.Planning includes advancing pediatric dilated cardiomyopathy into a single Phase 2 registrational trial in 2027, contingent on financing or a partnership.Alzheimer’s disease development is positioned for partnering and non-dilutive funding, based on an FDA-aligned single Phase 2/3 adaptive trial design that could support a future biologics license application.Capital plan targets lower cash burn and reduced dilution, supported by a March private placement for up to USD 30 million, with USD 15 million upfront and up to USD 15 million tied to ELPIS II results and sh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL4wmq0b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014005.SGD","LU0314104364.USD","BK4112","BK4588","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4139","LGVN","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","BK4585","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878518","title":"Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878518","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878518?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:05","pubTimestamp":1779307500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUA2MLJVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635557537","title":"Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635557537","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635557537?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:42","pubTimestamp":1778704943,"startTime":"0","endTime":"0","summary":"Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 44.12 percent increase over losses of $(0.34) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52545344/longeveron-q1-eps-0-19-misses-0-16-estimate-sales-398-000k-beat-314-667k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753739","title":"Longeveron Q1 revenue rises, beats analyst estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753739","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753739?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:24","pubTimestamp":1778703879,"startTime":"0","endTime":"0","summary":"Longeveron Q1 revenue rises, beats analyst estimatesOverviewUS biotech firm's Q1 revenue rose and beat analyst expectationsNet loss for Q1 narrowed from prior yearCompany closed $30 mln private placem","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q166:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758296","title":"BRIEF-Longeveron Q1 EPS USD -0.19","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758296","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758296?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702746,"startTime":"0","endTime":"0","summary":"BRIEF-Longeveron Q1 EPS USD -0.19\n\n\nMay 13 (Reuters) - Longeveron Q1 revenue USD 378 thousand.\n\nQ1 gross profit USD 264 thousand\nQ1 operating expenses USD 5.039 million\nQ1 income from operations USD -4.775 million\nQ1 net income USD -4.736 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXEDCA43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635581997","title":"Longeveron Q1 Revenue USD 378 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2635581997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635581997?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702701,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXEDCA43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758067","title":"Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758067","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758067?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702700,"startTime":"0","endTime":"0","summary":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3294435/0/en/Longeveron-Announces-2026-First-Quarter-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","BK4139","MSC","LGVN","BK4150","IND","BK4575","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635675828","title":"Longeveron Q1 net loss narrows 6% to $4.74 million; revenue rises to $398,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2635675828","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635675828?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:04","pubTimestamp":1778702681,"startTime":"0","endTime":"0","summary":"Longeveron posted a net loss of $4.74 million for the quarter ended March 31, 2026, narrowing 6% from a year earlier.Revenue in the quarter rose 4.46% to $398,000, while cost of revenues increased to $134,000.Operating loss improved to $4.78 million, as total operating expenses fell 7.64% to $5.04 million.Cash and cash equivalents totaled $15.8 million at March 31, 2026, with the company expecting that balance to fund operations into the fourth quarter of 2026.ELPIS II Phase 2b trial in hypoplastic left heart syndrome remains fully enrolled, with top-line results anticipated in August 2026 following an FDA Type C meeting that said right-ventricle ejection fraction is not an appropriate efficacy endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL4dYj9g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237211","title":"Longeveron reports DMC approval for laromestrocel study to continue as designed","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237211","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237211?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:09","pubTimestamp":1778530181,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced that the independent data monitoring committee, or DMC, has completed its final prespecified data review for the ongoin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-reports-dmc-approval-for-laromestrocel-study-to-continue-as-designed-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-reports-dmc-approval-for-laromestrocel-study-to-continue-as-designed-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634340442","title":"Longeveron Cut to Hold From Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2634340442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634340442?lang=en_us&edition=fundamental","pubTime":"2026-05-12 03:51","pubTimestamp":1778529060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LGVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 15:51 ET (19:51 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634823530","title":"Longeveron downgraded to Hold from Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2634823530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634823530?lang=en_us&edition=fundamental","pubTime":"2026-05-11 23:43","pubTimestamp":1778514209,"startTime":"0","endTime":"0","summary":"Maxim downgraded Longeveron (LGVN) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-downgraded-to-hold-from-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-downgraded-to-hold-from-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634128445","title":"Longeveron DMC clears Phase 2b HLHS stem cell trial to complete","url":"https://stock-news.laohu8.com/highlight/detail?id=2634128445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634128445?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:11","pubTimestamp":1778505068,"startTime":"0","endTime":"0","summary":"Longeveron disclosed an independent Data Monitoring Committee review that found no new safety concerns in its fully enrolled Phase 2b ELPIS II trial of laromestrocel in hypoplastic left heart syndrome, supporting completion of the study as planned.Results have not yet been presented; top-line data are expected in August 2026.Review outcome reduces near-term clinical hold risk, keeping a key rare-disease program on track ahead of a pivotal readout.Trial enrolled 40 pediatric patients across 12 US cardiac centers, with NIH-backed funding support cited for the study.Laromestrocel holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations for hypoplastic left heart syndrome, which could support an accelerated regulatory path if efficacy data are positive.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL4d2DrJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4139","IE00BN0W2T93.GBP","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","BK4588","LGVN","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284924","title":"Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2B Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (Hlhs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634284924?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:10","pubTimestamp":1778505000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA5XCLZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284120","title":"Longeveron Inc - Top-Line Results From Elpis Ii Trial Anticipated in August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634284120?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:10","pubTimestamp":1778505000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA5XCLZD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634228412","title":"Longeveron Inc - DMC Finds No Safety Concerns, Recommends Phase 2B Trial Continue to Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2634228412","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634228412?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:10","pubTimestamp":1778505000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA5XCLZD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":-0.0546},{"period":"1month","weight":-0.1648},{"period":"3month","weight":0.5095},{"period":"6month","weight":0.187},{"period":"1year","weight":-0.3814},{"period":"ytd","weight":0.4427}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.146765},{"month":2,"riseRate":0,"avgChangeRate":-0.052773},{"month":3,"riseRate":0.5,"avgChangeRate":0.193379},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.138428},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.132971},{"month":6,"riseRate":0.666667,"avgChangeRate":0.092819},{"month":7,"riseRate":0.6,"avgChangeRate":0.185232},{"month":8,"riseRate":0,"avgChangeRate":-0.329414},{"month":9,"riseRate":0.2,"avgChangeRate":-0.104571},{"month":10,"riseRate":0.4,"avgChangeRate":-0.0027},{"month":11,"riseRate":0.4,"avgChangeRate":1.29104},{"month":12,"riseRate":0,"avgChangeRate":-0.282059}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}